Jena, July 22 – Oncgnostics GmbH signs an agreement with Seegene Germany GmbH for the international distribution of its own tests. Dr. Alfred Hansel, Managing Director of Oncgnostics: “The agreement for worldwide distribution and the interest in the joint further development of our tests underpin our efforts to expand internationally.” Seegene Germany is a subsidiary of Seegene Inc. based in South Korea and is one of the world’s leading molecular diagnostics providers. In addition to worldwide distribution, the distribution agreement also includes exclusivity for the DACH region (Germany, Switzerland, Austria).

“With our new partner Seegene Germany, Oncgnostics is taking another major step towards internationalization,” says Hansel, who is responsible for international collaborations. Hansel and Oncgnostics Managing Director, Dr. Martina Schmitz, see Seegene’s expertise in the development and marketing of multiple tests, especially in infection diagnostics. According to management, the aim is not only to distribute the tests but also to jointly develop the Oncgnostics tests, which can then address the various international requirements. Hansel continues: “With Seegene as an international partner, we can better respond to the legal, sales and medical requirements of various countries worldwide.”

Dr. Lothar Kruska, Managing Director of Seegene Germany GmbH: “With the methylation tests from Oncgnostics GmbH, we are completing our portfolio in the field of HPV diagnostics. Oncgnostics’ technical basis and the clinical application of the tests fit very well into our product portfolio. Together with our HPV screening test, AllplexTM HR Detection, and the AllplexTM HPV 28 Detection Assay for comprehensive genotyping, we now offer a complete solution for improved early detection of cervical cancer. Many patients worldwide will benefit from the combination of our expertise. We look forward to working together.”

Seegene Germany GmbH

Seegene Germany GmbH was founded in 2017 as a German subsidiary of Seegene Inc. with headquarters in Seoul, South Korea. The company is a global leader in molecular diagnostics using multiplex real-time PCR. Seegene has 23 years of experience in research and development, manufacturing and operation of quantitative syndromic PCR technologies.

Oncgnostics GmbH

Oncgnostics GmbH, founded in 2012 as a spin-off from the University Women’s Hospital in Jena, specializes in the development of diagnostic tests based on epigenetic markers, specifically DNA methylation. The first CE IVD tests introduced to the market by Oncgnostics, GynTect® and ScreenYu Gyn®, are positioned in the area of cervical cancer. Oncgnostics leverages its expertise and technological platforms to develop further diagnostic tests, currently focusing on head and neck tumors.

 

Photo: oncgnostics GmbH
From left to right: Dr. Alfred Hansel; Dr. Jong-Yoon Chun (Founder and CEO Seegene Inc., South Korea); Dr. Martina Schmitz, Dr. Lothar Kruska (CEO Seegene Germany GmbH).